Feder v. Bristol-Myers Squibb Co.

33 F. Supp. 2d 319, 1999 U.S. Dist. LEXIS 417, 75 Empl. Prac. Dec. (CCH) 45,882, 79 Fair Empl. Prac. Cas. (BNA) 241, 1999 WL 32932
CourtDistrict Court, S.D. New York
DecidedJanuary 20, 1999
Docket97 Civ. 7030 (LAK)
StatusPublished
Cited by9 cases

This text of 33 F. Supp. 2d 319 (Feder v. Bristol-Myers Squibb Co.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Feder v. Bristol-Myers Squibb Co., 33 F. Supp. 2d 319, 1999 U.S. Dist. LEXIS 417, 75 Empl. Prac. Dec. (CCH) 45,882, 79 Fair Empl. Prac. Cas. (BNA) 241, 1999 WL 32932 (S.D.N.Y. 1999).

Opinion

OPINION

KAPLAN, District Judge.

This is a so-called “glass ceiling” case. Roslyn Feder, M.D., Ph.D., a senior vice president in the Worldwide Medicines Group at Bristol-Myers Squibb Company (“BMS”), alleges that defendant, motivated by gender animus solely on the part of the president of her group, 1 denied her advancement in the company in violation of Title VII of the Civil Rights Act of 1964 and comparable state and local laws. 2 Feder claims also that BMS retaliated against her for complaining of bias, filing a charge of sex discrimination with the Equal Employment Opportunity Commission (“EEOC”), and filing this lawsuit. She asserts a common law breach of contract claim as well.

The Court previously granted in part and denied in part defendant’s motion for summary judgment dismissing Feder’s claims. This opinion sets forth the basis for that decision.

Background

Dr. Roslyn Feder entered college at 16 and a joint M.D./Ph.D program at 19. In 1984, she received both an M.D. from Cornell University Medical School and a Ph.D. in cell biology from Rockefeller University. She spent the following two years working as a senior consultant for Arthur D. Little, Inc. while completing a clinical fellowship in pediatrics at the Harvard Medical School. 3

Although Feder had no formal business education, 4 she began a business career in 1988 when she accepted a position with San-doz Pharmaceuticals Corporation (“Sandoz”) as assistant director of licensing. She was promoted twice during the next six years, attaining the position of executive director of Business Development and Licensing. 5

Feder Hired by BMS

Feder’s career at Sandoz was not an entirely happy one. Her position involved no direct managerial responsibilities, 6 she believed that she was “not always well liked,” 7 and she felt that she was not fairly compensated. 8 By some time in 1994, she concluded that she had learned all that she could at Sandoz and contemplated leaving. 9 Feder *322 was interested in finding a new position that would further her goal of a “high powered, quick trajectory career” and bring her “power, money, career development and growth.” 10 At the same time, BMS, an international pharmaceutical company with headquarters in New York, was searching to fill the position of vice president, Worldwide Business Development and Licensing in its Pharmaceutical Group.

In February 1995, with the approval of Kenneth Weg, president of the Pharmaceutical Group, 11 BMS offered this position, which reported to Dr. Andrew Bodnar, then president, Oncology/Immunology and Worldwide Strategic Business Development, to Feder. Feder testified at her deposition that Kenneth Sloan, senior vice president of Human Resources for the Pharmaceutical Group, told her “that he expected — that it was the expectation that Dr. Bodnar would not remain in this position long, and that ... it was the expectation that [she] would succeed Dr. Bodnar in his position.” 12 According to Fed-er, she relied on this statement in accepting BMS’s offer. 13

Hayden’s 1995 Promotion

The forecast that Bodnar would not long remain in his position proved correct, but the alleged expectation as to Bodnar’s successor did not. In September 1995, Bodnar was transferred out of the Pharmaceutical Group and the position he held restructured. 14 But Weg promoted Donald Hayden, Jr., then responsible for BMS’s oncology-immunology business, rather than Feder into the restructured position. Hayden, a 14-year veteran of BMS, was given responsibility for both the Franchise Management and Business Development and Licensing units, the latter of which was headed by Feder. In this capacity, he began reporting directly to Weg. 15 Feder, who now argues that she should have reported directly to Weg, began reporting to Hayden. 16

The February 1997 Reorganization

In late 1996 or early 1997, Weg decided to reorganize the Pharmaceutical Group. Under his initial proposal, Hayden would have replaced Samuel Hamad, then president of Intercontinental. 17 Richard Hinson, an experienced executive who nevertheless was relatively new to BMS, would have replaced Hayden as senior vice president for Worldwide Franchise Management and Business Development. 18 Christine Poon, another woman in BMS’ Pharmaceutical Group, would have reported to Hayden while Feder would have reported to Hinson. 19

Poon objected to the proposed reorganization. It appears that she thought she ought to report to Weg, inasmuch as he had run BMS’s Latin American operations at one time, and that reporting to him would be an important career development for her. 20 Hayden too disagreed with the proposed structure, believing it inappropriate for Poon and Feder, each of whom was quite experienced in her area, to report to Hayden and Hinson, respectively, because Hayden and *323 Hinson had comparatively little experience in their specific new areas of responsibility. 21 Faced with this opposition, Weg revised the proposal. He promoted both Poon and Hayden and divided Intercontinental between them, making Poon responsible for Latin America and Canada and Hayden for all other non-European international markets. 22 Weg also restructured Hayden’s prior position, separating Franchise Management from Business Development and Licensing. Hayden maintained responsibility for Licensing and Business Development, 23 and Hinson was promoted to senior vice president for Worldwide Franchise Management. Feder, her position unchanged, continued to report to Hayden. She, however, was designated to lead a “high impact initiative” for external development 24 and appointed to the Worldwide Medicines Group operating committee. 25

Shortly after the announcement of these organizational changes, Feder expressed her dissatisfaction with the reporting structure to Weg 26

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Young v. Brennan
D. Massachusetts, 2018
Wilson v. Brennan
213 F. Supp. 3d 934 (S.D. Ohio, 2016)
Joseph v. Owens & Minor Distribution, Inc.
5 F. Supp. 3d 295 (E.D. New York, 2014)
Darden v. Town of Stratford
420 F. Supp. 2d 36 (D. Connecticut, 2006)
Smith v. AVSC International, Inc.
148 F. Supp. 2d 302 (S.D. New York, 2001)
Pascal v. Storage Technology Corp.
152 F. Supp. 2d 191 (D. Connecticut, 2001)
Bombero v. Warner-Lambert Co.
142 F. Supp. 2d 196 (D. Connecticut, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
33 F. Supp. 2d 319, 1999 U.S. Dist. LEXIS 417, 75 Empl. Prac. Dec. (CCH) 45,882, 79 Fair Empl. Prac. Cas. (BNA) 241, 1999 WL 32932, Counsel Stack Legal Research, https://law.counselstack.com/opinion/feder-v-bristol-myers-squibb-co-nysd-1999.